Press releases
- Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
- Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
- Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
- Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
- Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
- Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
More ▼
Key statistics
As of last trade Palatin Technologies Inc (PTN:BRN) traded at 1.70, 0.00% above its 52-week low of 1.70, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.70 |
---|---|
High | 1.70 |
Low | 1.70 |
Bid | 1.59 |
Offer | 1.60 |
Previous close | 1.70 |
Average volume | -- |
---|---|
Shares outstanding | 16.14m |
Free float | 15.60m |
P/E (TTM) | -- |
Market cap | 32.11m USD |
EPS (TTM) | -2.39 USD |
Data delayed at least 15 minutes, as of Mar 08 2024.
More ▼